Search for Terms or Answers
Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz
Read Article
Smolen, Kerschbaumer, Aletaha, and Robinson have published a comprehensive review article of rheumatoid arthritis (RA) in JAMA, noting significant changes to our understanding and treatment guidelines.
Read Article
Dr. John Cush @RheumNow( View Tweet )
Prof. Valmed, a large language model (LLM) cleared by European regulators for medical diagnosis, outperformed human physicians for diagnosing rheumatologic conditions in terms of speed but not accuracy, a randomized trial showed.
Read Article
Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical practice.
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!
Read Article
A meta-analysis of Janus kinase (JAKi) inhibitors clinical trials in rheumatoid arthritis (RA) has shown higher BMI was associated with poorer responses and a reduced treatment benefit with JAK inhibitors in RA patients.
Read Article
If laughter is the best medicine, then music has to be second best. A new scoping review in Pain Reports by Bradt et al., examines the effect of music-based interventions (MBIs) on pain management. While its efficacy is well established, how or why music relieves pain has never been fully
Read Article
The proposed approach to difficult-to-treat rheumatoid arthritis is based on the EULAR definition (having failed 2 or more b/tsDMARDs). The authors provide guidance in the form of an easy acronym, A B C D E, which covers both diagnostic and therapeutic considerations.
Read Article
Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-
Read Article
Cancer is a major cause of mortality in systemic sclerosis (SSc). A nested case-control study within EUSTAR registry shows distinct patterns of cancer related temporally to SSc, serologic profiles and traditional cancer risk factors.
Cancers were
The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.
Read Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Read Article
RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.
Read Article
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
Read Article
Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
Read Article
Epidemiologic estimates on systemic lupus erythematosus (SLE) diagnosis are limited. The Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Read Article
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
